ArticleInternational journal of cancer2018

Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.

Yang Ge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.